罗氏Roche Holdings（RHHBY）2025年第一季度财务业绩电话会演示报告（含附录）「OTC」（英文版）（167页）.pdf

1、This presentation contains certain forward-looking statements.These forward-looking statements may be identified by words such as believes,expects,anticipates,projects,intends,should,seeks,estimates,future or similar expressions or by discussion of,among other things,strategy,goals,plans or intentio

2、ns.Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation,among others:1pricing and product initiatives of competitors;2legislative and regulatory developments and economic conditions;3 delay or in

3、ability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery,development or marketing of new products or new uses of existing products,including without limitation negative

4、results of clinical trials or research projects,unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 litigation;10 loss of key executives

5、 or other employees;and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the histo

6、rical published earnings or earnings per share of Roche.For marketed products discussed in this presentation,please see full prescribing information on our website All mentioned trademarks are legally protected.RocheQ1 2025 salesBasel,24 April 2025GroupThomas SchineckerChief Executive Officer Perfor